Abstract
Personalized MedicineVol. 9, No. 5 EditorialThe need to assess drugs selected from cancer genomic data prior to patient treatmentPeter ToliasPeter ToliasDepartment of Chemistry, Chemical Biology & Biomedical Engineering, Interdepartmental Bioinnovation Program, Stevens Institute of Technology, 507 River Street, Castle Point on Hudson, McLean Hall Room 515, Hoboken NJ 07030, USA. Search for more papers by this authorEmail the corresponding author at ptolias@stevens.eduPublished Online:30 Jul 2012https://doi.org/10.2217/pme.12.51AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: 3D microfluidic culturecancerdrug selection and assessmenttumor biopsywhole-genome sequencingReferences1 Sennino B, Ishiguro-Oonuma T, Wei Y et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov.2(3),270–287 (2012).Crossref, Medline, CAS, Google Scholar2 Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med.366,883–892 (2012).Crossref, Medline, CAS, Google Scholar3 Wang L, Lawrence MS, Wan Y et al.SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med.365(26),2497–2506 (2011).Crossref, Medline, CAS, Google Scholar4 Stark MS, Woods SL, Gartside MG et al. Frequent somatic mutations in and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet.44,165–169 (2011).Crossref, Medline, Google Scholar5 Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell148,409–420 (2012).Crossref, Medline, CAS, Google Scholar6 Lipson D, Capelletti M, Yelensky R et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med.18,382–384 (2012).Crossref, Medline, CAS, Google Scholar7 Perel P, Roberts I, Sena E et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ334(7586),197 (2007).Crossref, Medline, CAS, Google Scholar8 Hyman AH, Simons K. The new cell biology: beyond HeLa cells. Nature480,34 (2011).Crossref, Medline, CAS, Google Scholar9 Chapman S, Liu X, Meyers C, Schlegel R, McBride AA. Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor. J. Clin. Invest.120,2619–2626 (2010).Crossref, Medline, CAS, Google Scholar10 Liu X, Ory V, Chapman S et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol.180(2),599–607 (2012).Crossref, Medline, CAS, Google Scholar11 Bell E. Why 3D is better than 2D. Nat. Rev. Immunol.6,87 (2006).Crossref, Google Scholar12 Lee JH, Wang H, Kaplan JB, Lee WY. Microfluidic approach to create three- dimensional tissue models for biofilm-related infection of orthopaedic implants. Tissue Eng. Part C Methods17,39–48 (2011).Crossref, Medline, CAS, Google Scholar13 Lee JH, Gu Y, Wang H, Lee WY. Microfluidic 3D bone tissue model for high-throughput evaluation of wound-healing and infection-preventing biomaterials. Biomaterials33,999–1006 (2012).Crossref, Medline, CAS, Google Scholar14 Desrochers TM, Shamis Y, Alt-Holland A et al. The 3D tissue microenvironment modulates DNA methylation and E-cadherin expression in squamous cell carcinoma. Epigenetics7,34–46 (2012).Crossref, Medline, CAS, Google Scholar101 The International Cancer Genome Consortium. https://www.icgc.orgGoogle ScholarFiguresReferencesRelatedDetailsCited ByWell plate-based perfusion culture device for tissue and tumor microenvironment replication1 January 2015 | Lab on a Chip, Vol. 15, No. 13A possible future for the pharmaceutical industryPeter Tolias1 December 2014 | Personalized Medicine, Vol. 11, No. 8 Vol. 9, No. 5 Follow us on social media for the latest updates Metrics Downloaded 129 times History Published online 30 July 2012 Published in print July 2012 Information© Future Medicine LtdKeywords3D microfluidic culturecancerdrug selection and assessmenttumor biopsywhole-genome sequencingFinancial & competing interests disclosureThe author is a co-inventor on two provisional patent applications dealing with the design of microfluidic devices that can culture cells in 3D (US 61/566,261 and US 61/568,681). The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
